Cargando…

Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer

BACKGROUND: Non-small cell lung cancers (NSCLC) are highly heterogeneous at the molecular level and comprise 75% of all lung tumors. We have previously shown that the receptor tyrosine kinase (RTK) MET frequently suffers gain-of-function mutations that significantly promote lung tumorigenesis. Subse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanteti, Rajani, El-Hashani, Essam, Dhanasingh, Immanuel, Tretiakova, Maria, Husain, Aliya N, Sharma, Sherven, Sharma, Jay, Vokes, Everett E, Salgia, Ravi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3995599/ https://www.ncbi.nlm.nih.gov/pubmed/24628993 http://dx.doi.org/10.1186/1471-2407-14-185

Ejemplares similares

Role of protein kinase C β and vascular endothelial growth factor receptor in malignant pleural mesothelioma: Therapeutic implications and the usefulness of Caenorhabditis elegans model organism
por: Loganathan, Sivakumar, et al.
Publicado: (2011)

CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2010)

PI3 Kinase Pathway and MET Inhibition is Efficacious in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2016)

Correction: CBL Is Frequently Altered in Lung Cancers: Its Relationship to Mutations in MET and EGFR Tyrosine Kinases
por: Tan, Yi-Hung Carol, et al.
Publicado: (2011)

MET and PI3K/mTOR as a Potential Combinatorial Therapeutic Target in Malignant Pleural Mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2014)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
por: Tan, Yi-Hung Carol, et al.
Publicado: (2017)

The EphB4 Receptor Tyrosine Kinase Promotes Lung Cancer Growth: A Potential Novel Therapeutic Target
por: Ferguson, Benjamin D., et al.
Publicado: (2013)

C. elegans and mutants with chronic nicotine exposure as a novel model of cancer phenotype
por: Kanteti, Rajani, et al.
Publicado: (2015)

Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer
por: Ferguson, Benjamin D., et al.
Publicado: (2015)

MET/PKCß expression correlate with metastasis and inhibition is synergistic in lung cancer
por: Faoro, Leonardo, et al.
Publicado: (2009)

O-6-methylguanine-deoxyribonucleic acid methyltransferase methylation enhances response to temozolomide treatment in esophageal cancer
por: Hasina, Rifat, et al.
Publicado: (2013)

Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma
por: Rolle, Cleo E., et al.
Publicado: (2016)

Sphingosine Kinase 1 Is Required for Mesothelioma Cell Proliferation: Role of Histone Acetylation
por: Kalari, Satish, et al.
Publicado: (2012)

MET and RON receptor tyrosine kinases in colorectal adenocarcinoma: molecular features as drug targets and antibody-drug conjugates for therapy
por: Yao, Hang-Ping, et al.
Publicado: (2020)

Autoinhibition of the Ron receptor tyrosine kinase by the juxtamembrane domain
por: Wang, Xin, et al.
Publicado: (2014)

An Introduction and Overview of RON Receptor Tyrosine Kinase Signaling
por: Hunt, Brian G., et al.
Publicado: (2023)

Focal adhesion kinase a potential therapeutic target for pancreatic cancer and malignant pleural mesothelioma
por: Kanteti, Rajani, et al.
Publicado: (2018)

Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion
por: Ma, P C, et al.
Publicado: (2007)

FAK and paxillin, two potential targets in pancreatic cancer
por: Kanteti, Rajani, et al.
Publicado: (2016)

Regulation of Macrophage Polarization by RON Receptor Tyrosine Kinase Signaling
por: Chaudhuri, Amitabha
Publicado: (2014)

Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets
por: Chang, Katherine, et al.
Publicado: (2015)

RON tyrosine kinase mutations in brain metastases from lung cancer
por: Milan, Melissa, et al.
Publicado: (2018)

Significance of the entire C-terminus in biological activities mediated by the RON receptor tyrosine kinase and its oncogenic variant RON160
por: Lu, Yi, et al.
Publicado: (2008)

RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer
por: Weng, Tian-Hao, et al.
Publicado: (2020)

Aberrant RON and MET Co-overexpression as Novel Prognostic Biomarkers of Shortened Patient Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Pancreatic Cancer
por: Hu, Chen-Yu, et al.
Publicado: (2019)

Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients
por: Poroyko, Valeriy, et al.
Publicado: (2018)

Variant RONΔ160 of the RON receptor tyrosine kinase promotes the growth and invasion in vitro and in vivo in gastric cancer cell lines
por: Zhou, Dong-Hui, et al.
Publicado: (2015)

12-05-2009 14 38 Interview met Ron Howard,...
Publicado: (2009)

The Receptor Tyrosine Kinase RON and Its Isoforms as Therapeutic Targets in Ewing Sarcoma
por: Berning, Philipp, et al.
Publicado: (2020)

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
por: Surati, Mosmi, et al.
Publicado: (2011)

Utilisation of a thoracic oncology database to capture radiological and pathological images for evaluation of response to chemotherapy in patients with malignant pleural mesothelioma
por: Carey, George B, et al.
Publicado: (2012)

Crystal Structure of the Sema-PSI Extracellular Domain of Human RON Receptor Tyrosine Kinase
por: Chao, Kinlin L., et al.
Publicado: (2012)

The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies
por: Cazes, Alex, et al.
Publicado: (2022)

Receptor Tyrosine Kinases and Inhibitors in Lung Cancer
por: Pisick, Evan, et al.
Publicado: (2004)

When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
por: Baird, Anne-Marie, et al.
Publicado: (2019)

THE RON RECEPTOR TYROSINE KINASE POSITIVELY REGULATES ANGIOGENIC CHEMOKINE PRODUCTION IN PROSTATE CANCER CELLS
por: Thobe, Megan N., et al.
Publicado: (2009)

Evidence for 2-Methoxyestradiol-Mediated Inhibition of Receptor Tyrosine Kinase RON in the Management of Prostate Cancer
por: Batth, Izhar Singh, et al.
Publicado: (2021)

MicroRNA Expression Profiling of Lung Cancer with Differential Expression of the RON Receptor Tyrosine Kinase
por: Ou, Huilin, et al.
Publicado: (2021)

Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer
por: Wu, Zheng, et al.
Publicado: (2015)

Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder
por: Cheng, H-L, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_t43cvsgkrkk58j9d33049j74cs